| Medical and Health Sciences | Lifetime | 708 | GB 77 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 19 | GB 3 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 84 | GB 7 | 99.92 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 297 | GB 36 | 99.10 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 7 | GB 2 | 99.98 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 17 | GB 4 | 99.86 |
| Cardiovascular Function and Risk Factors | Lifetime | 21 | GB 1 | 99.93 |
| Heart Failure Treatment and Management | Lifetime | 26 | GB 2 | 99.90 |
| Cardiac pacing and defibrillation studies | Lifetime | 48 | GB 2 | 99.78 |
| Diabetes Treatment and Management | Lifetime | 79 | GB 10 | 99.60 |
| Cardiovascular Issues in Pregnancy | Lifetime | 350 | GB 38 | 97.09 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 597 | GB 55 | 97.29 |
| Cardiovascular Disease and Adiposity | Lifetime | 692 | GB 48 | 96.70 |
| Potassium and Related Disorders | Lifetime | 202 | GB 12 | 96.19 |
| GDF15 and Related Biomarkers | Lifetime | 181 | GB 12 | 90.82 |
| Heart rate and cardiovascular health | Lifetime | 150 | GB 13 | 90.43 |
| Medication Adherence and Compliance | Lifetime | 884 | GB 65 | 90.47 |
| Erythropoietin and Anemia Treatment | Lifetime | 837 | GB 56 | 89.76 |
| Sex and Gender in Healthcare | Lifetime | 306 | GB 18 | 85.63 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 3 | GB 1 | 99.97 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 5 | GB 1 | 99.86 |
| Heart Failure Treatment and Management | 2021-2025 | 5 | GB 2 | 99.96 |
| Diabetes Treatment and Management | 2021-2025 | 19 | GB 5 | 99.83 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 26 | GB 4 | 98.22 |
| Hormonal Regulation and Hypertension | 2021-2025 | 23 | GB 3 | 98.70 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 133 | GB 10 | 97.42 |
| Pancreatic function and diabetes | 2021-2025 | 140 | GB 20 | 97.20 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 487 | GB 71 | 95.73 |
| Potassium and Related Disorders | 2021-2025 | 37 | GB 3 | 96.90 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 565 | GB 58 | 96.37 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 179 | GB 17 | 94.25 |
| Diabetes Management and Research | 2021-2025 | 391 | GB 45 | 95.45 |
| Heart rate and cardiovascular health | 2021-2025 | 8 | GB 1 | 92.89 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 424 | GB 28 | 94.53 |
| Medication Adherence and Compliance | 2021-2025 | 122 | GB 6 | 91.54 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 228 | GB 20 | 90.29 |
| Nutrition and Health in Aging | 2021-2025 | 990 | GB 72 | 91.03 |
| Health and Medical Research Impacts | 2021-2025 | 126 | GB 8 | 87.42 |
| Cardiac Health and Mental Health | 2021-2025 | 404 | GB 31 | 89.53 |
| Cardiovascular and exercise physiology | 2021-2025 | 770 | GB 59 | 87.87 |
| GDF15 and Related Biomarkers | 2021-2025 | 127 | GB 8 | 80.55 |
| Electrolyte and hormonal disorders | 2021-2025 | 470 | GB 27 | 72.58 |
| Pharmacology and Obesity Treatment | 2021-2025 | 609 | GB 39 | 68.45 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 895 | GB 11 | 62.57 |
| Sex and Gender in Healthcare | 2021-2025 | 325 | GB 33 | 63.94 |
| Biomedical and Engineering Education | 2021-2025 | 652 | GB 30 | 61.85 |